caa a22 4500 469074272 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF01741794 doi (NATIONALLICENCE)springer-10.1007/BF01741794 Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA [Elektronische Daten] [Howard Hubbell, George Gibson, Robert Bigler] Summary: Lymphokine-activated killer (LAK) cell activity was measured in human peripheral blood mononuclear cells (PBMC) treated in vitro for 3 days with recombinant interleukin-2 (rIL-2) and mismatched double-stranded RNA (dsRNA). Lytic activity was measured utilizing K562 (NK-sensitive) and 786-0 (NK-resistant) target cells. PBMC cultured with rIL-2 (10-1000 BRMP U/ml) alone showed concentration-dependent lytic activity against the 786-0 target cells, while cells cultured in unsupplemented medium or medium supplemented with mismatched dsRNA (200 µg/ml) alone could not lyse the 786-0 targets. The combination of mismatched dsRNA with suboptimal concentrations of rIL-2 (10-30 U/ml) showed enhancement of both natural killer (NK) and LAK cell activities. The uptake of [3H]thymidine by treated effector cells was dependent on time and rIL-2 concentration and was not increased in the cells treated with low-dose rIL-2/mismatched dsRNA, compared to those treated with low-dose rIL-2 or mismatched dsRNA alone. Similarly, changes in the expression of CD3, CD4, CD8, CD57, CD16 and CD25 cell surface antigens were dependent on rIL-2 concentration and not altered by the presence of mismatched dsRNA. These results indicate that mismatched dsRNA can potentiate rIL-2-induced LAK cell activity by increasing the functional activity per cell, rather than by increasing the number of activated cells. Springer-Verlag, 1992 Mismatched dsRNA nationallicence Interleukin-2 nationallicence LAK activity nationallicence Hubbell Howard Department of Neoplastic Diseases, Hahnemann University, Broad and Vine, 19102, Philadelphia, Pennsylvania, USA aut Gibson George Department of Neoplastic Diseases, Hahnemann University, Broad and Vine, 19102, Philadelphia, Pennsylvania, USA aut Bigler Robert Department of Neoplastic Diseases, Hahnemann University, Broad and Vine, 19102, Philadelphia, Pennsylvania, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 34/4(1992-07-01), 259-264 0340-7004 34:4<259 1992 34 262 https://doi.org/10.1007/BF01741794 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741794 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hubbell Howard Department of Neoplastic Diseases, Hahnemann University, Broad and Vine, 19102, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Gibson George Department of Neoplastic Diseases, Hahnemann University, Broad and Vine, 19102, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 700 1- Bigler Robert Department of Neoplastic Diseases, Hahnemann University, Broad and Vine, 19102, Philadelphia, Pennsylvania, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/4(1992-07-01), 259-264 0340-7004 34:4<259 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer